Skip to main content
Premium Trial:

Request an Annual Quote

Komen to Fund Cancer PGx Research through New Grants

NEW YORK (GenomeWeb News) – Susan G. Komen for the Cure, a non-profit organization dedicated to funding breast cancer research and education, has awarded $60 million in grants to US and international researchers, including nearly $19 million to fund research into pharmacogenomics.

The funding for the pharmacogenomic research is provided through the organization's Promise Grants.

Komen, along with the Triple Negative Breast Cancer Foundation, has awarded $6.4 million to the University of Alabama at Birmingham to study adding a new drug, along with chemotherapy in treating triple negative breast cancer. That research project includes looking for ways to predict which therapies will be most effective for triple negative breast cancer patients.

Indiana University will receive a $5.8 million Promise Grant to identify biomarkers to predict which breast cancer patients will benefit from the drug bevacizumab (Avastin), and which patients will suffer significant side effects from use of the drug.

Researchers at Thomas Jefferson University in Philadelphia will use a $6.7 million Promise Grant to find biomarkers to predict treatment response and match patients with the best treatment option.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.